The analysis of efficacy and safety of tislelizumab versus pembrolizumab with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma
10.3969/j.issn.1006-5725.2025.07.014
- VernacularTitle:替雷利珠单抗联合化疗对比帕博利珠单抗联合化疗一线治疗晚期肺鳞癌患者的疗效
- Author:
Yufei ZHU
1
;
Zhihao HUANG
;
Yichen CAI
;
Yunyun ZENG
;
Huiyi HUANG
;
Jun SUN
;
Shan SU
Author Information
1. 广州医科大学研究生院(广东 广州 511495)
- Publication Type:Journal Article
- Keywords:
tislelizumab;
pembrolizumab;
chemotherapy;
advanced lung squamous cell carcinoma
- From:
The Journal of Practical Medicine
2025;41(7):1024-1029
- CountryChina
- Language:Chinese
-
Abstract:
Objective The study aimed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus pembrolizumab combined with chemotherapy as first-line treatments for advanced lung squa-mous cell carcinoma.Methods We retrospectively reviewed and analyzed the medical records of 116 patients with advanced lung squamous cell carcinoma treated with first-line chemotherapy plus tislelizumab or pembrolizumab in Guangzhou Chest Hospital from September 2020 to April 2024.We focused on analysis of time to treatment failure(TTF)and objective response rate(ORR)as well as disease control rate(DCR)and treatment-related adverse events(TRAEs).Results At a median follow up of 19.7 monyhs,the median TTF was 9.7 months in the tislelizumab group and 7.7 months in the pembrolizumab group(P<0.05).In addition,the ORR in the tislelizumab group was significantly higher than that in the pembrolizumab group(77.6%vs.60.3%,P<0.05),with DCRs of 93.1%and 87.9%,respectively(P=0.342).Regarding safety,the proportions of grade 3 or higher TRAEs and any-grade TRAEs were comparable between the two groups:29.3%and 81.0%in the tislelizumab group,and 32.8%and 87.9%in the pembrolizumab group,respectively.The most common TRAEs in both groups were hematological toxicities.Conclusions Tislelizumab plus chemotherapy demonstrated better efficacy and safety compared to pembrolizumab with chemotherapy as first-line treatment for Chinese patients with advanced lung squamous cell carcinoma.
